Skip to main content

Table 3 Hazard ratio risks and log-rank tests in BR1141

From: Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value

  BRmet50   PMID18271932Sig33 PMID16505416Sig822
  HR(95% CI) HR P HR (95% CI) HR P HR (95% CI) HR P
Tumor size       
T1 2.6(1.3-5.5) 0.009 2.4(1.1-5.0) 0.019 1.0(0.5-2.1) 0.943
T2 1.7(1.0-2.8) 0.044 2.0(1.3-3.3) 0.008 0.7(0.4-1.2) 0.209
Lymph node involvement       
No 2.3(1.4-3.9) 0.001 2.2(1.3-3.3) 0.003 0.8(0.5-1.4) 0.511
Yes 2.0(1.0-4.1) 0.053 2.8(1.4-5.0) 0.004 0.6(0.3-1.4) 0.245
Tamoxifen treatment       
No 2.6(1.4-5.0) 0.004 2.5(1.3-5.0) 0.007 1.1(0.5-2.0) 0.869
Yes 2.2(1.2-3.9) 0.007 2.6(1.4-5.0) 0.001 0.6(0.3-1.0) 0.041
Differentiation       
Good 2.3(0.6-8.4) 0.196 2.5(0.8-10) 0.131 1.3(0.4-3.8) 0.682
Intermediate 2.5(1.5-4.3) 0.001 3.3(2.0-5.0) <0.001 0.7(0.4-1.2) 0.194
Poor 1.4(0.6-3.4) 0.442 1.3(0.6-3.3) 0.554 0.5(0.2-1.1) 0.086
ER status       
Negative 1.4(0.5-4.0) 0.495 1.7(0.6-5.0) 0.329 0.9(0.3-2.4) 0.782
Positive 2.5(1.6-4.0) <0.001 2.5(1.7-5.0) <0.001 0.7(0.4-1.1) 0.102
  1. Note: T1 denotes tumor size less than or equal to 2.0 cm, and T2 denotes tumor size larger than 2.0 cm.
  2. HR: Hazard ratio value.
  3. HR P: Hazard ratio P value.